Metallothionein overexpression in human brain tumours

被引:27
作者
Maier, H
Jones, C
Jasani, B
Ofner, D
Zelger, B
Schmid, KW
Budka, H
机构
[1] UNIV VIENNA, INST NEUROL, VIENNA, AUSTRIA
[2] UNIV WALES COLL MED, DEPT PATHOL, CARDIFF CF4 4XN, S GLAM, WALES
[3] UNIV WALES COLL MED, IMMUNOCYTOCHEM & MOL PATHOL UNIT, CARDIFF CF4 4XN, S GLAM, WALES
[4] UNIV INNSBRUCK, DEPT SURG 1, A-6020 INNSBRUCK, AUSTRIA
[5] UNIV MUNSTER, GERHARD DOMAGK INST PATHOL, D-4400 MUNSTER, GERMANY
关键词
metallothioneins; gliomas; meningiomas; immunohistochemistry;
D O I
10.1007/s004010050755
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Metallothioneins (MTs) are metal binding proteins overexpressed in various human neoplasms which are associated with resistance to cytotoxic drugs. A series of 156 archival human brain tumours were investigated immunohistochemically for expression of MTs; these included 10 low-grade gliomas, 44 high-grade gliomas, 98 meningeal rumours (19 classical, 30 atypical, 38 anaplastic meningiomas, and 11 haemangiopericytomas or papillary meningiomas), and 4 other rumours. Low-grade gliomas showed heterogeneous MT expression; 32 high-grade gliomas (72.7%) showed MT expression of more than 25% of tumour cells without statistically significant differences between first operations and recurrent tumours. In 2 glioblastomas, the presence of MT was confirmed by Western blotting. The extent of MT immunoexpression showed a statistically significant inverse relationship to the degree of p53 immunoreactivity. In meningiomas, a tendency to a higher percentage of MT-expressing cells was observed from classical over atypical to anaplastic meningiomas, but these differences were not statistically significant. In conclusion, MT expression is present in a significant portion of, especially malignant, brain rumours and might be involved in their poor response to antineoplastic drugs.
引用
收藏
页码:599 / 604
页数:6
相关论文
共 50 条
[1]  
ANDREWS PA, 1987, CANCER CHEMOTH PHARM, V19, P149
[2]   WET AUTOCLAVE PRETREATMENT FOR ANTIGEN RETRIEVAL IN DIAGNOSTIC IMMUNOHISTOCHEMISTRY [J].
BANKFALVI, A ;
NAVABI, H ;
BIER, B ;
BOCKER, W ;
JASANI, B ;
SCHMID, KW .
JOURNAL OF PATHOLOGY, 1994, 174 (03) :223-228
[3]  
CAVALLO F, 1991, CANCER, V67, P738, DOI 10.1002/1097-0142(19910201)67:3<738::AID-CNCR2820670335>3.0.CO
[4]  
2-#
[5]  
CHERIAN MG, 1978, LIFE SCI, V23, P1
[6]  
CHERIAN MG, 1993, CANCER RES, V53, P922
[7]  
CHIN JL, 1993, CANCER, V72, P3029, DOI 10.1002/1097-0142(19931115)72:10<3029::AID-CNCR2820721027>3.0.CO
[8]  
2-6
[9]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[10]   DIVALENT METAL-IONS INDUCE CONFORMATIONAL CHANGE IN PURE, HUMAN WILD-TYPE P53 TUMOR-SUPPRESSOR PROTEIN [J].
COFFER, AI ;
KNOWLES, PP .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1994, 1209 (02) :279-285